Please assess the completion status of the following clinical trial:

Trial Title: A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* History of allergic rhinitis/rhinoconjunctivitis to house dust of 1 year duration or more (with or without asthma)~* If female of childbearing potential, has a negative urine pregnancy test at screening and agrees to remain abstinent or use (or have their partner use) 2 acceptable methods of birth control within the projected duration of the study.~Exclusion Criteria:~* Sensitized and regularly exposed to animal dander and molds, (e.g. present in the home, job, etc.)~* Sensitized and regularly exposed to seasonal allergens (i.e., birch or grass pollen)~* Immunosuppressive treatment within 3 months prior to screening (except steroids for allergic and asthma symptoms)~* History of chronic urticaria and/or angioedema within 2 years prior to screening~* Previous immunotherapy treatment with any HDM allergen for more than 1 month within 3 years prior to screening~* Ongoing treatment with any specific immunotherapy~* History of anaphylaxis with cardiorespiratory symptoms with prior immunotherapy, due to an unknown cause or to an inhalant allergen~* Unstable uncontrolled/partially controlled or severe asthma, or life-threatening asthma attack or an occurrence of any clinical deterioration of asthma that resulted in emergency treatment, hospitalization due to asthma, or treatment with systemic corticosteroids (but allowing short-acting beta agonists \[SABA\]) within 3 months prior to screening~* Asthma requiring medium- or high-dose inhaled corticosteroid (ICS) within 12 months prior to screening~* Chronic sinusitis within 2 years prior to screening~* Nasal condition that could confound the efficacy or safety assessments (e.g., nasal polyps)~* Pregnant, breastfeeding or planning to become pregnant during the study~* Participation in a different investigational study at any site during the same time frame of this study~* Direct association with the administration of the study or a family member of the study staff

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo rapidly dissolving tablet administered sublingually once daily (q.d.), at approximately the same time each day, for 24 weeks
- MK-8237 6 Developmental Units (DU) (Type: EXPERIMENTAL): MK-8237 6 DU rapidly dissolving tablet administered sublingually q.d., at approximately the same time each day, for 24 weeks
- MK-8237 12 DU (Type: EXPERIMENTAL): MK-8237 12 DU rapidly dissolving tablet administered sublingually q.d., at approximately the same time each day, for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).